HEMLIBRA uniquely addresses the factor deficiency of hemophilia A

HEMLIBRA is a therapeutic bispecific monoclonal antibody that restores the hemostatic process

HEMLIBRA bridges FIXa and FX, allowing the coagulation cascade to continue

  • HEMLIBRA has a lower binding affinity than FVIIIa to FIXa and FX and does not interfere with exogenous FVIII binding to FIXa and FX1
    • In vitro, HEMLIBRA demonstrated a 100-times lower binding affinity for FIXa and a 6-times lower binding affinity for FX, as compared with FVIIIa 1

HEMLIBRA does not cause or increase FVIII inhibitors and remains active in their presence

FIXa=activated factor IX; FVIII=factor VIII; FVIIIa=activated FVIII; FX=factor X; QW=once a week; Q2W=every 2 weeks; Q4W=every 4 weeks; SD=standard deviation.

Sustained therapeutic drug levels across dosing options

HEMLIBRA has a half-life of 4 weeks

Sustained mean (±SD) trough plasma concentrations of HEMLIBRA at steady-state were 51.2±15.2 μg/mL, 46.9±14.8 μg/mL, and 38.5±14.2 μg/mL with the recommended maintenance dosing of 1.5 mg/kg QW, 3 mg/kg Q2W, and 6 mg/kg Q4W, respectively.
  • Steady-state drug concentrations were achieved after the 4 QW loading doses and sustained with QW, Q2W, and Q4W maintenance doses
  • The steady-state plasma trough concentrations of HEMLIBRA were comparable in adult and pediatric patients older than 6 months at equivalent weight-based doses
    • Lower concentrations of HEMLIBRA were predicted in pediatric patients less than 6 months old

HEMLIBRA Clinical Trials

Learn more about our clinical trials for patients with or without FVIII inhibitors

HEMLIBRA Experiences

See healthcare professionals share their personal experience in treating with HEMLIBRA